Paper Details

Paper Title

Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.

Paper Journal Title

Eur Urol

Paper Citation Count

Paper Publication Year

2023

Bio Mention

Cancer, GG1 cancers, Patient, Prostate Adenocarcinoma, cancer, grade group 1 (, prostate cancer

Mesh Descriptor

Author Name	Affiliation
Holger Moch	University Hospital Zurich
Holger Moch	University Hospital Zurich
Mark A Rubin	Bern Center for Precision Medicine, University of Bern and Inselspital
Mark A Rubin	Bern Center for Precision Medicine, University of Bern and Inselspital
John R Srigley	University of Toronto
Daniel M Berney	Barts Cancer Institute, Queen Mary University of London and Department of Cellular Pathology, Barts Health NHS Trust

Column Actions